{
  "$schema": "https://themachinepress.com/schemas/story-v1.schema.json",
  "schema_version": "1.0.0",
  "document_type": "machine_press_story",
  "story": {
    "story_id": "mp-2026-07-19-003",
    "source_story_id": "tmp-story-fluvoxamine-long-covid-fatigue",
    "edition_id": "mp-2026-07-19-morning-0010",
    "edition_url": "https://themachinepress.com/edition/2026-07-19",
    "position": 3,
    "story_type": "dispatch",
    "section": "research",
    "editorial_classification": "editorial",
    "headline": "An Antidepressant Clears a Long-COVID Trial",
    "slug": "an-antidepressant-clears-a-long-covid-trial",
    "dek": "In a 399-person randomized trial, fluvoxamine reduced persistent fatigue and improved reported quality of life.",
    "summary": "In a 399-person randomized trial, fluvoxamine reduced persistent fatigue and improved reported quality of life.",
    "body_text": "The REVIVE-TOGETHER trial enrolled 399 adults in Brazil with fatigue lasting at least 90 days after confirmed SARS-CoV-2 infection. Participants received fluvoxamine, metformin, or placebo for 60 days. Fluvoxamine outperformed placebo on fatigue and quality-of-life measures, while metformin did not improve established fatigue. The adaptive trial offers evidence for one symptom in one study population; the authors say further work must identify who benefits and how the drug fits into broader long-COVID care.",
    "why_it_matters": "In a 399-person randomized trial, fluvoxamine reduced persistent fatigue and improved reported quality of life.",
    "limitations": [
      "Fluvoxamine outperformed placebo on fatigue and quality-of-life measures, while metformin did not improve established fatigue."
    ],
    "importance": 9,
    "canonical_url": "https://themachinepress.com/story/mp-2026-07-19-003/an-antidepressant-clears-a-long-covid-trial",
    "json_url": "https://themachinepress.com/story/mp-2026-07-19-003.json",
    "first_published_at": "2026-07-19T09:00:00.000-04:00",
    "modified_at": "2026-07-19T09:00:00.000-04:00",
    "content_status": "new",
    "is_carryover": false,
    "carryover_reason": null,
    "key_claims": [
      {
        "claim_id": "claim-mp-2026-07-19-003-001",
        "text": "In a 399-person randomized trial, fluvoxamine reduced persistent fatigue and improved reported quality of life.",
        "source_ids": [
          "source-2026-07-19-003"
        ],
        "qualification": "Fluvoxamine outperformed placebo on fatigue and quality-of-life measures, while metformin did not improve established fatigue."
      }
    ],
    "source_ids": [
      "source-2026-07-19-003"
    ],
    "tags": [
      "long COVID",
      "fluvoxamine",
      "clinical trial"
    ],
    "image_url": "https://themachinepress.com/issues/2026-07-19/long-covid-research-file-image.webp",
    "corrections": []
  },
  "sources": [
    {
      "source_id": "source-2026-07-19-003",
      "title": "McMaster University via ScienceDaily: Fluvoxamine and long-COVID fatigue",
      "publisher": "McMaster University via ScienceDaily",
      "url": "https://www.sciencedaily.com/releases/2026/07/260718010158.htm",
      "canonical_url": "https://www.sciencedaily.com/releases/2026/07/260718010158.htm",
      "source_type": "secondary_reporting",
      "is_primary_source": false,
      "published_at": null,
      "accessed_at": "2026-07-19T08:27:22.202-04:00",
      "supports_claim_ids": [
        "claim-mp-2026-07-19-003-001"
      ]
    }
  ],
  "corrections": [],
  "publisher": {
    "name": "The Machine Press",
    "url": "https://themachinepress.com",
    "description": "A daily newspaper for the age of artificial intelligence."
  },
  "cite_this_report": {
    "title": "An Antidepressant Clears a Long-COVID Trial",
    "publisher": "The Machine Press",
    "published_at": "2026-07-19T09:00:00.000-04:00",
    "canonical_url": "https://themachinepress.com/story/mp-2026-07-19-003/an-antidepressant-clears-a-long-covid-trial"
  }
}